KW:NYSEKennedy-Wilson Holdings Inc. Analysis
Data as of 2026-06-09 - not real-time
$11.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Kennedy‑Wilson is trading just above its 20‑day SMA ($11.01 vs $11.01) and the 50‑day SMA ($10.94), signaling a short‑term bullish bias, yet the MACD histogram is negative and the signal line is bearish, while volume is on a decreasing trend – a classic divergence that hints at weakening momentum. Fundamentally, the stock appears severely overvalued with a trailing P/E of 91.7 versus an industry average of 32.4, a payout ratio of 400% that makes the 4.36% dividend unsustainable, and a debt‑to‑equity ratio above 300% driven by a $1.8 billion senior notes issuance. Cash flow is negative (operating cash flow –$24.6 M) and free cash flow is also negative, while ROE (5%) and ROA (0.8%) are weak. Recent news of a large debt raise and an investigation into board fiduciary duties adds governance and financial risk.
Given the mixed technical picture, extreme valuation stretch, high leverage, and pending legal scrutiny, the stock faces upside pressure only if a strategic sale or restructuring materializes; otherwise, downside risk remains significant.
Given the mixed technical picture, extreme valuation stretch, high leverage, and pending legal scrutiny, the stock faces upside pressure only if a strategic sale or restructuring materializes; otherwise, downside risk remains significant.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish MACD divergence with falling volume
- Extreme P/E relative to peers
- Upcoming $1.8B senior notes adding leverage
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential sale or restructuring could unlock value
- High dividend yield may attract income seekers despite sustainability concerns
- Moderate beta (0.39) limits price volatility
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Unsustainable debt load and negative cash flow
- Governance risk from fiduciary‑duty investigation
- Overvaluation with limited growth prospects
Key Metrics & Analysis
Financial Health
Revenue Growth-0.80%
Profit Margin10.93%
P/E Ratio91.7
ROE4.95%
ROA0.83%
Debt/Equity312.16
P/B Ratio2.0
Op. Cash Flow$-24600000
Free Cash Flow$-22425000
Industry P/E32.4
Technical Analysis
TrendBullish
RSI54.1
Support$10.97
Resistance$11.04
MA 20$11.01
MA 50$10.94
MA 200$9.81
MACDBearish
VolumeDecreasing
Fear & Greed Index87.64
Valuation
Target Price$9.00
Upside/Downside-18.18%
GradeOvervalued
TypeValue
Dividend Yield4.36%
Risk Assessment
Beta0.39
Volatility3.34%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.